^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    SafeSEQ CRC MRD assay

    Company:
    Sysmex Corp
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    2years
    Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial (COSA 2022)
    P3 | "All received adjuvant 5-Fluorouracil-based chemotherapy...A third patient with late recurrence did not have detectable ctDNA. Analyses in the larger cohort (n=368) are underway."
    P3 data • Clinical • Circulating tumor DNA
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
    |
    KRAS G12V • KRAS G13D • KRAS G12 • KRAS G13 • NRAS G13
    |
    SafeSEQ CRC MRD assay
    |
    5-fluorouracil
    over2years
    Tumour naïve circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial (ESMO 2022)
    Results All pts (26 female; median age 69; 16 high risk stage II, 35 III) received adjuvant 5-Fluorouracil based chemotherapy (32 with oxaliplatin, 4 had neoadjuvant chemoradiation for rectal cancer) and median follow-up was 60 months. Table: 380P conclusions In 51 ASCOLT pts with high risk resected CRC following adjuvant chemotherapy, 6 of 10 with reported recurrences had detectable cfDNA using a tumour naïve SafeSEQ assay. Analyses in the larger cohort (n = 368) are underway.
    P3 data • Clinical • Circulating tumor DNA
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
    |
    SafeSEQ CRC MRD assay
    |
    5-fluorouracil • oxaliplatin